Physician profile
Weiyan Tan
NPI 1174511000
$19,823.79
in general payments reported to CMS, 2019-2025
40 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,136 · 2020: $1,449 · 2021: $2,525 · 2022: $2,673 · 2023: $2,159 · 2024: $2,792 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,040.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,643.63 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals Lp | $1,832.13 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,656.47 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $1,475.00 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $1,464.50 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $928.21 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $919.62 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $692.87 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $667.36 | 2019-2025 | Xifaxan |
| Amgen INC. | $633.24 | 2019-2025 | Evenity, Repatha, Repatha |
| Amarin Pharma, INC. | $502.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $461.63 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $376.44 | 2019-2022 | |
| Exact Sciences Corporation | $244.91 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $226.22 | 2021-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiyan Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.